Elotuzumab作用机制 https://www.emplicitihcp.com/about/mechanism-of-action Elotuzumab具有双重作用机制(既激活,又抑制),发挥免疫调节作用。 结合自然杀伤细胞(NK cell)表面的SLAMF7,直接激活免疫系统。 标记多发性骨髓瘤表面的SLAMF7,从而和NK细胞表面的CD16结合,引发抗体依赖性细胞毒作用(ADCC),促使免疫系统杀伤肿...
While the primary mechanism of action of elotuzumab in pre-clinical in vitro studies has been shown to be antibody-dependent cellular cytotoxicity (ADCC) mediated via NK-cell CD16, other possible mechanisms of activity of elotuzumab in MM are not well defined. Specifically, the downstream ...
showed that elotuzumab can inhibit MM cell adhe- sion to BMSCs and may overcome the stimulatory ef- fects of BMSCs on MM growth and survival in co- culture experiments [13], indicating that targeting myeloma-microenvironment interaction is an add- itional anti-myeloma mechanism of elotuzumab ...
Monoclonal antibodies offer a unique and different action from what we are used to using. This new mechanism of action is very important for those patients who don’t have other options. In the newly diagnosed population, it may offer us a higher percentage of patients who are cured. Is the...
Mechanism Of Action Elotuzumab is a humanized IgG1 monoclonal antibody that specifically targets the SLAMF7 (SignalingLymphocyticActivation Molecule Family member 7) protein. SLAMF7 is expressed on myeloma cells independent of cytogenetic abnormalities. SLAMF7 is also expressed on Natural Killer (NK) cel...
Elotuzumab binds a unique epitope on the membrane IgC2 domain of SLAMF7, exhibiting a dual mechanism of action: natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity (ADCC) and enhancement of NK cell activity. The ADCC is mediated through engagement between Fc portion of ...
Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab. Leukemia. 2015;29(10):2039–49. Article CAS Google Scholar Moreno L, Perez C, Zabaleta A, Manrique I, Alignani D, Ajona D, et al. The mechanism of action of the ...
compared with a 70% decrease of B cells following rituximab and 65%–100% decrease on all subsets following alemtuzumab in the same experiment.18 Mechanisms of actions of elotuzumab Most work suggests that the predominant mechanism of action of elotuzumab is NK cell-mediated ADCC (Figure 2) and...
Elotuzumab has a dual mechanism of action to specifically kill myeloma cells: binding SLAMF7 on myeloma cells facilitates natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity (ADCC), and direct engagement of SLAMF7 on NK cells further enhances NK cell activity. Elotuzumab ...
SLAMF7 also exists as a soluble form (sSLAMF7) and has been detected in the serum of patients with MM at statistically significant higher levels than healthy individuals. Although the mechanism of action of elotuzumab involves the direct activation of natural killer cells and the initiation of ...